JHJean-Luc Harousseau

Jean-Luc Harousseau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Luc Harousseau has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment of Multiple Myeloma and Related Disorders

    by S. Vincent Rajkumar, Robert A. Kyle, Rafael Fonseca, P. Leif Bergsagel, A. Keith Stewart, Sagar Lonial, Jonathan L. Kaufman, Marc S. Raab, Paul G. Richardson, Kenneth C. Anderson, et al.

    Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. This book is aimed at the practitioner who is looking to put these advances into clinical context. It will serve as an up-to-date resource for treatment of myeloma and related disorders. Chapters are written by international authorities and contain color photos, diagrams, and algorithms outlining preferred treatment strategies. Relevant scientific information is integrated throughout, but the focus here is on providing practical therapeutic guidance for oncologists and hematologists caring for myeloma patients. The book covers all myeloma subtypes and related disorders, including amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, MGUS, and POEMS syndrome.


  • The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal insufficiency

    by J. Blade, P. Sonneveld, J. San Miguel, H. Sutherland, R. Hajek, A. Nagler, A. Spencer, T. Robak, J. L. Harousseau, R. Z. Orlowski

    8562 Background: Renal dysfunction (RD) is common in patients with multiple myeloma (MM) and has been associated with poor outcomes. Orlowski et al, 2007, demonstrated that pegylated liposomal doxorubicin (PLD) + bortezomib (B) for pts with relapsed/refractory MM who have received at least one prior therapy significantly increased median time to progression (TTP) (9.3 vs. 6.5 months, p = 0.00004) compared with B alone. We wished to determine the efficacy and feasibility of PLD + B in relapsed/refractory MM patients with renal insufficiency (RI) (creatinine clearance (CrCl) < 60 ml/min). Methods: Eligible pts who were randomized received bolus IV B 1.3 mg/m2 on days 1, 4, 8 and 11 of each 3-week cycle (n = 322) or the same B regimen plus IV PLD 30 mg/m2 on day 4 (n = 324) of each cycle. 193 pts with RI from this trial were analyzed retrospectively to determine the impact of RI on the efficacy and safety of PLD + B, as well as the effect on renal function. Pts with severe RI (CrCl ≤ 30 ml/min) were excluded. Results: The mean number of PLD + B cycles administered was comparable between the two subgroups (5.1 in the RI subgroup vs. 5.0 in the non-RI subgroup). For the RI subgroup, median TTP was 10.9 (95% CI: 9.1, n/a) and 6.5 (95% CI: 5.3, 7.2) months in the PLD + B and B arms, respectively (p = 0.002). These results are consistent with the benefit of PLD + B demonstrated in the overall study population. There was a steady improvement in renal function over the course of treatment in both the PLD + B and B treatment arms. The incidence of grade 3/4 anemia, diarrhea and pneumonia were more common than in the RI subgroup compared to the non-RI group. Conclusion: RI does not compromise the efficacy or tolerability of PLD + B in relapsed/refractory MM pts. Treatment with PLD + B or B alone appears to improve renal function in relapsed/refractory MM pts with RI.


  • Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial

    by J. L. Harousseau, C. Mathiot, M. Attal, G. Marit, D. Caillot, C. Hullin, T. Facon, I. Webb, H. Avet-Loiseau, P. Moreau

    8505 Background: ASCT is the standard of care for MM patients (pts) aged ≤65 yrs with high complete plus very good partial remission (CR+VGPR) rate. Improving CR rate has been associated with prolonged PFS and OS. Phase 2 studies have shown bortezomib (VELCADE)/dexamethasone (Vel/Dex) as an effective induction therapy. Methods: In this phase 3 study, Vel/Dex (4 cycles) was compared with vincristine/doxorubicin/dexamethasone (VAD; 4 cycles) as induction prior to ASCT in 482 MM pts aged ≤65 years. Primary objective was CR+near-CR (nCR) rate. Planned enrolment (480 pts) provided 80% power to detect a 10% difference in CR+nCR rate (10% vs 20%). Consolidation with 2 cycles of Dex, cyclophosphamide, etoposide, platinum (DCEP) was also evaluated. Pts were randomized to 4 arms: A1: VAD (N=121), A2: VAD+DCEP (N=121), B1: Vel/Dex (N=121), and B2: Vel/Dex+DCEP (N=119). Results: In the intent-to-treat analysis (ITT) Vel/Dex had significantly higher CR+nCR/≥VGPR vs VAD post-induction (21.3%/46.7% vs 8.3%/18.6%, P=0.0023/3mg/L or ≤3mg/L β2M and in pts with or without del(13). The significant CR+nCR/≥VGPR Vel/Dex advantage was maintained post-ASCT, both in pts who received ASCT (40.8%/71.8% vs 28.8%/51%, P=0.0089/6 CD34+/kg) in 97% and 99% of Vel/Dex and VAD pts, respectively. First analyses of the survival data will be presented at the meeting. Conclusion: Vel/Dex significantly improved post-induction response rates vs VAD, which translated into significantly better ≥VGPR rates post-ASCT. Vel/Dex should now be considered the standard induction treatment prior to ASCT.


  • Open Access

    Induction Therapy in Multiple Myeloma

    by Jean-Luc Harousseau

    In most hematologic malignancies the role of induction treatment is to achieve complete remission (CR). In multiple myeloma this has been possible only with the introduction of high-dose therapy plus autologous stem-cell transplantation (ASCT). In the context of ASCT there is a statistical relationship between CR or very good partial remission (VGPR) achievement and progression-free survival or overall survival. High-dose therapy consists of 3 to 6 courses of a dexamethasone alone or combined with vincristine-adriamycin (VAD) to reduce the tumor burden and the plasma cell infiltration followed by 1 or 2 courses of high-dose melphalan plus ASCT. This treatment induces 20% to 40% CR and 40% to 55% CR/VGPR. The introduction of novel agents in the induction treatment is changing this scenario. The combinations of dexamethasone with thalidomide, bortezomib or lenalidomide increase the CR/VGPR rates compared to dexamethasone or VAD. Triple combinations are currently being evaluated, but preliminary results with not more than 3 or 4 cycles show post-ASCT CR/VGPR rates of 60% to 75%In elderly patients who are not candidates for ASCT, combinations of melphalan-prednisone with a novel agent (thalidomide, bortezomib or lenalidomide) yield CR/VGPR rates that are quite comparable to those achieved in younger patients with ASCT. Prolonged treatment with the combination of lenalidomide plus dexamethasone can be administered safely and appears to induce very high (up to 70%) CR/VGPR rates as well.


  • Preface

    by Jean-Luc Harousseau

  • The allogeneic dilemma

    by J-L Harousseau

    The place of allogeneic SCT in the management of multiple myeloma remains controversial. Although it may induce long-term clinical and molecular remissions, the very high transplant-related toxicity after a myeloablative preparative regimen has limited its role to younger patients as first-line treatment option. Even with this limited indication, toxic death rate related to infections and GVHD is considered too high and this strategy has been almost abandoned. Reduced intensity conditioning (RIC) regimens look promising, as the transplant-related mortality is low even with matched unrelated donors and can be considered for older patients up to the age of 65 years. However when used in patients with a high tumor burden or with chemo-resistant disease, the immunologic effect of the graft is not sufficient to avoid relapses. Therefore, RIC allotransplantation is currently used after tumor mass reduction with high-dose therapy followed by autologous SCT. A recently published Italian study shows that this strategy induces better event-free survival than double autologous SCT due to a reduced relapse rate. The questions raised by this encouraging result are discussed in this paper.


  • A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia

    by Jean-Luc Harousseau, Jeffrey E. Lancet, Josy Reiffers, Bob Lowenberg, Xavier Thomas, Francoise Huguet, Pierre Fenaux, Steven Zhang, Wayne Rackoff, Peter De Porre, et al.

    This phase 2 study evaluated the efficacy and safety of the oral farnesyltransferase inhibitor tipifarnib in adults with refractory or relapsed acute myeloid leukemia (AML). Patients (n = 252) received tipifarnib 600 mg twice a day for 21 days in 28-day cycles. Median age was 62 years; 99 (39%) patients were 65 years or older. Eleven (4%) of 252 patients achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp; 9 CR and 2 CRp). Nineteen patients (8%), including those who achieved CR/CRp, achieved a reduction in bone marrow blasts to less than 5% blasts. Bone marrow blasts were reduced more than 50% in an additional 8 patients (total = 27; 11%). Median survival was 369 days for patients who achieved CR/CRp. Myelosuppression was the most common adverse event. The most common nonhematologic toxicities were fever, nausea, and hypokalemia. Single-agent treatment with tipifarnib induced durable CR/CRp, which was associated with prolonged survival, in some patients with refractory or relapsed AML. The response rate observed in this heavily pretreated group of patients suggests the requirement to enhance the response rate either by combining tipifarnib with other active agents or determining factors that are predictive of response.


  • Role of Bone Marrow Transplantation in the Disease Pathway of Myeloma

    by Jean-Luc Harousseau, Philippe Moreau

    In multiple myeloma, autologous stem cell transplantation (ASCT) has been considered a standard of care in younger patients. The introduction of novel agents (i.e., thalidomide, lenalidomide, and bortezomib) may change this scenario. These agents can be administered before or after ASCT with the goal of increasing the complete remission (CR) rate and prolonging remission. For instance, thalidomide given as maintenance therapy after double ASCT increases CR rate, event-free survival (EFS), and overall survival. Moreover, combinations of conventional chemotherapy with novel agents such as thalidomide or bortezomib yield CR rates and EFS comparable to those achieved with standard single ASCT. Prospective randomized studies are needed to evaluate the impact of novel agents versus or in combination with ASCT. Myeloablative conditioning regimens before allogeneic stem cell transplantation are being replaced with concurrent autologous-transplantation and reduced-intensity conditioning allogeneic stem cell transplantation. Transplant-related mortality associated with this procedure is lower, but more follow-up is needed before definite conclusions can be drawn.